A pair of studies provide insight into the increased risk of dysglycemia among women with PCOS and the potential influence of combined oral contraceptive pills on this risk in a population-based cohort.
Data from a phase 2 study of women with overweight or obesity and polycystic ovary syndrome suggests use of licogliflozin was associated with significant reductions in hyperinsulinemia and androgenemia in this patient population.
A comparison of women with PCOS to matched controls indicates women with PCOS were at a 26% greater risk of experiencing major adverse cardiovascular events than their counterparts without polycystic ovary syndrome.
A meta-analysis of nearly a dozen studies presented at ENDO 2021 suggests Black women with PCOS were at an increased cardiometabolic risk, despite having comparable fasting glucose and lower triglyceride levels.
An analysis of data from more than 9 million women details the increased odds of developing gestational diabetes, gestational hypertension, and other complications associated with having polycystic ovary syndrome.